Intravenous Magnesium in Patients Receiving Cisplatin

Status Completed

Clinical Trial Summary

This research study, is trying to determine the highest dose of magnesium that can be given safely to people with malignant mesothelioma receiving intraoperative chemotherapy with cisplatin who are at risk for acute kidney injury. The name(s) of the study drug involved in this study is - magnesium sulfate.

Clinical Trial Description

This research study is a phase 1 pilot study, which is the first time investigators are examining larger doses of magnesium in patients receiving cisplatin and the effect of intravenous magnesium administration on blood magnesium levels. In previous studies it was found that patients with lower blood magnesium levels were at higher risk of acute kidney injury. The study is looking to determine the best dose(s) of intravenous magnesium to administer safely without severe or unmanageable side effects in participants. The purpose of the study is also to determine the dose of intravenous magnesium needed to achieve a target level. The U.S. Food and Drug Administration (FDA) has not approved magnesium for people with mesothelioma receiving cisplatin but it has been approved for other uses. The research study procedures include: screening for eligibility and study treatment at participant's preoperative visit with their thoracic surgeon. Intravenous magnesium will be administered in the hospital, the night prior to surgery, and take place over 36 hours. Participants will followed for 4 days on postoperative days 1, 2, and 3. It is expected that about 10 people will take part in this research study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04481672
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	Phase 1
Start date	July 30, 2021
Completion date	December 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01950572` - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated	`NCT01624090` - Mithramycin for Lung, Esophagus, and Other Chest Cancers	Phase 2
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05415098` - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas	Phase 1
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT06057935` - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2
Terminated	`NCT02838745` - Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Recruiting	`NCT01912547` - Thromboelastography During Surgery for Malignant Pleural Mesothelioma	Phase 0
Completed	`NCT01521325` - A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers	Phase 1
Recruiting	`NCT02073500` - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Recruiting	`NCT00996385` - Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma	Phase 2
Completed	`NCT02467426` - Isolated Thoracic Perfusion (ITP-F) for MPM	Phase 2
Completed	`NCT00407459` - Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00787410` - An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma	Phase 2
Terminated	`NCT01907100` - Nintedanib (BIBF 1120) in Mesothelioma	Phase 2/Phase 3
Completed	`NCT04056026` - A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma	Early Phase 1
Completed	`NCT02903914` - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03319537` - Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma	Phase 1/Phase 2
Terminated	`NCT03685591` - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors	Phase 1